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 Chronic Fatigue Syndrome (CFS)/ Myalgic 
Encephalomyelitis (ME) and Fibromyalgia (FM): The 
foundation of a relationship. 
Introduction 
Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME) and Fibromyalgia 
(FM) are disabling syndromes, without an established aetiology, a diagnostic test, or 
curative treatment.1-3 Currently these complex syndromes are governed by their own 
individual diagnostic criteria and management direction, but display overwhelming 
evidence of similar symptoms. The prevalence of CFS/ME is estimated that in General 
Practice 10 patients in 10,000 (0.4%) are likely to have CFS/ME.4,5  The prevalence of 
FM has been recorded as 2-3% of the population.5 
Early research addressing the similarities of CFS/ME and FM dates back to the 1990’s,  
most of which were preformed prior to the development and publishing of the accepted 
American Centre for Disease Control (CDC) Criteria 6 for diagnosis CFS/ME (Table 1), 
and when the American College of Rheumatology (ACR)7 diagnostic criterion for FM was 
in its infancy. These may be obsolescent, but are relevant in the context of the current 
research. Much of the literature available may discuss CFS/ME and FM together, 
however little research actually investigates if the symptom experience is the same.1,4, 8-
14 The National Institute for Health and Care Excellence (NICE)8 published guidelines in 
2007 for the management of CFS/ME, which are currently under review. CFS/ME 
comprises a broad range of complex symptoms which include headaches, muscle aches 
and pains and/or joint pain.8  FM is characterised by chronic widespread musculoskeletal 
pain which persists for > 3 months, with pain in 11 of the 18 identified pain points (Fig 1 
and 2 illustrated by the dots on the body diagrams).2,7 Symptoms include: flu like and 
gastrointestinal symptoms; pain; fatigue; sleep disturbance; anxiety and/or depression; 
impact on self esteem and reduced Quality of Life.8,14 Evidence suggests that pain is one 
of the prominent symptoms associated with both syndromes, although historically this 
has been one of the dividing factors during diagnosis, when the similarities between 
these syndromes outweigh the differences.7,8, 11, 15,16  Confirming a diagnosis of CFS/ME 
or FM is a long and complex processes due to the subtle differences in the initial 
presenting symptoms.8,11,14   Evaluating the evidence presented in context with medical 
advances and increasing investment in research, suggested a need to revisit this area of 
study.  Considering these issues and to provide the most appropriate evidence based 
care, it is important to investigate these syndromes, as similar management strategies 
may be beneficial for both groups.  
US Case Definition of Chronic Fatigue Syndrome (Fukuda et al, 1994) 
1. medically unexplained chronic fatigue, of new onset  > 6 months, which is 
2. not substantially alleviated by rest, not the result of ongoing exertion,  
3. substantial reduction in occupational, educational, social and personal activities. 
4.  Anxiety and depression are  not always excluded 
The following conditions, if present, exclude diagnosis of CFS: past or current major depression with 
melancholic or psychotic features, delusional disorders, bipolar disorders, schizophrenia, anorexia nervosa, 
bulimia, or alcoholic or substance abuse within 2 years before the onset of CFS or any time afterward. 
 
2. > 4 or more symptoms, occur for  > 6 months  These are 
Self reported persistent or recurrent impairment in short-term memory or concentration severe enough to 
cause substantial reductions in previous levels of occupational, educational, social, or personal activities 
a) Sore throat 
b) Tender cervical lymph or axillary lymph nodes 
c) Muscle pain 
d) Multiple joint pain without joint redness or swelling 
e) Headaches of a new type, pattern or severity 
f) Unrefreshing sleep. 
g) Post exertional malaise lasting more than 24 hours. 
 
Table 1: US Case Definition of Chronic Fatigue Syndrome6 
 
The purpose of this, the first phase was primarily to confirm the symptoms and their 
severity in CFS/ME and FM and to identify any occurring themes.  At present in the 
absence of evidence confirming CFS/ME and FM share the same underlying 
pathology, it may be reasonable to suggest they have strong overlapping 
symptoms, which should be afforded all the same management options.  The 
evidence presented will create the foundation of the second phase, to establish if 
a relationship exists between the symptoms of CFS/ME and FM. 
Methods 
Participants 
People self selected to participate and were recruited through advertisements on the 
internet and through CFS/ME and FM self help groups. Participants were aged > 16 with 
a confirmed diagnosis of CFS/ME or FM from a General Practitioner (GP) or specialist 
were included.  Participants with CFS/ME were required to satisfy the requirements of 
the American (CDC) Criteria for CFS/ME6 and participants with FM were required to 
satisfy the ACR Criteria.7 Suitability for inclusion was based on screening answers to 
questions.  Exclusions were as a result of any additional chronic conditions or anxiety 
and depression, self diagnosis, or incomplete data sets.   
 
Consent 
A web-based template (www.cfsfibromy.co.uk) was designed to capture data using a 
number of questionnaires.  Informed consent was confirmed electronically, and may 
have been retracted up to the point of data analysis.  Ethical approval for this study was 
granted by the appropriate University. 
 
Data Collection 
Nine questionnaires had formerly been subject to validity and reliability checks and 
reflect the main symptoms and issues which impact people with CFS/ME and FM (Table 
1).  These sections comprised the disease specific questionnaire for CFS/ME, the 
American CDC Symptom Inventory and diagnostic criterion for CFS/ME,6, 17 and for FM 
the ACR diagnostic criterion for FM7  and the Fibromyalgia Impact Questionnaire 
(FIQ).18, 19, 20 
 
The remaining questionnaires measured symptoms identified, as follows: The McGill 
Pain Questionnaire (MPQ);21 The Pittsburgh Sleep Quality Index (PSQI);22 The 
Multidimensional Fatigue Inventory (MFI);23 The Hospital Anxiety and Depression Scale 
(HADS);24 The Health Related Quality of Life (HRQoL) (SF-36 V2) Questionnaire;25 The 
Multidimensional Health Locus of Control Scale (MHLOC Form C)26 and The Rosenberg 
Self-Esteem Scale (RSES).27 Each questionnaire had its own discrete set of instructions, 
with a consent section at the beginning, detailed in Table 2. 
 
In addition, questions were posed to collect demographic and comprehensive 
information on the sample.  Details of the research were presented to facilitate the 
participants submitting their consent.  Data were manually screened to confirm all 
questionnaires were fully completed and submitted, prior to analysis.   
 
Symptom Questionnaire Purpose Scoring Reliability Validity Author 
 
Specific 
Questionnaire/ 
Criteria  
    
 
Diagnostic 
Criteria for 
CFS/ME 
American 
Centre for 
Disease Control 
(CDC) 
Diagnostic 
Criteria for 
CFS/ME.  
Diagnostic 
criteria.  See 
Table 1.  In 
addition 
measures, 
frequency, 
No Cut off 
scores > 6 
months of 
symptoms 
More than 
4 
Good 
Cronbachs 
alpha (α) 
ranging 
from 0.82-
0.91 
r >0.7717 44 
Good 
Significa
nt 
correlati
ons  r = 
0.64-
.094( p< 
Fukuda et 
al., 1994.  
 
 Wagner et 
al., 2005 
 
Symptom 
Inventory 
intensity and 
duration of 8 
symptoms  
 
45 0.001)17 
44 
Diagnostic 
Criteria for 
FM 
American 
College of 
Rheumatology 
Diagnostic 
Criteria for FM 
Diagnostic criteria for 
FM. 
Fig 1 and 2 illustrate 
pain points 
No cut off 
score > 11 
out of 18 
tender 
points 
n/a n/a 
Wolfe et 
al., 1990. 
Symptom 
experience 
of FM 
The  
Fibromyalgia 
Impact 
Questionnaire 
(FIQ) 
Comprises 20 items to 
assess the impact of 
symptoms of FM on 
patients’ daily lives 
and their response to 
any 
management/treatme
nt offered. Questions 
address patient’s 
function, pain level, 
fatigue, sleep 
disturbance and 
psychological distress.  
 
 
Scores > 
50 
confirmed 
FM >70 
Severe FM 
Good 
α = 0.72 - 
0.93 
r  = 0.58 to 
0.8318 19 
Good 
Significa
nt 
correlati
ons With 
the 
Arthritis 
Impact 
Scale 
( p< 
0.0001)46 
 
Burkhardt 
et al., 
1991. 
 
 Generic Questionnaire  
     
Pain 
McGill Pain 
Questionnaire 
(MPQ) 
Measures  frequency 
and intensity of pain, 
namely: Affective,  
Evaluative,  Sensory  
and miscellaneous.  
There is a body 
diagram to indicate 
areas of pain, 72 
descriptor words to 
assess pain, and pain 
rating intensity scale.  
Each section is scored 
based on the 
guidelines. 
No cut off 
score. 
Higher 
scores are 
indicative of 
an 
increased 
level of 
pain. 
 
Good 
α>0.9 
r >0.89 
( P<0.001)21 
47 
Good 
Co-
efficient
s 
ranging 
between 
0.3 and 
0.421 
Melzack, 
1975. 
 
Fatigue 
Multidimension
al Fatigue 
Inventory (MFI) 
Measures 20 items on 
5 dimensions: 
general, physical, 
mental, reduced 
motivation and 
reduced activity.  
Each dimension 
contains four items, 
two items relating to 
fatigue and two items 
which are contra 
indicative of fatigue.   
  
Scores 
range from 
4 -20.  
Domains 
should not 
be summed 
together.  
High scores 
indicative of 
high levels 
of fatigue.  
A score of 
> 10 on the 
reduced 
activity 
subscale, 
and severe 
fatigue is 
highlighted 
by a score 
Good 
α>0.80 with 
average of 
0.84 
Stability r > 
0.7223 48 
Good 
P<0.001 
High 
scores 
0.77 
general 
fatigue, 
0.7 
physical 
fatigue, 
0.61 
reduced 
activity, 
0.56 
reduced 
motivati
on 
mental 
fatigue 
0.23 
Smets et 
al., 1995. 
 
of > 13 on 
the general 
fatigue 
scale. 
 
(p<0.01)2
3 48 
Sleep 
Quality 
The Pittsburgh 
Sleep Quality 
Index (PSQI) 
Measures seep over 
the period of 1 month. 
Comprising 19 items 
generating seven 
component scores 
measuring; subjective 
sleep quality, sleep 
latency, sleep 
duration, habitual 
sleep efficiency, sleep 
disturbance, the use 
of sleeping 
medication, and day-
time dysfunction  
Each scale 
scores 0 
(no 
difficulty) to 
3 (severe 
difficulty), 
which 
yields a 
score from 
0 to 21.  
High scores 
indicate 
poor sleep 
quality and 
a global 
score of > 5 
indicates 
sleep 
disturbance
,  
Good 
α > 0.83 
Mean 
component 
scores r = 
0.58 
Individual 
items 
α>0.83 
r  > 0.85 
(p<0.0001)22 
49 50 
Good 
r = 0.33 
(p<0.001
)22 49 
Buysse et 
al., 1988. 
 
Quality of 
Life 
The SF-36 V2 
Questionnaire 
(SF-36 V2) 
Comprises  36 
questions within 8 
domains of health 
namely: pain general 
health, Vitality, 
Physical functioning, 
Social functioning, 
Role limitations 
through physical 
problems, Role 
limitations due to 
emotional problems 
and mental health 
including anxiety, 
depression, loss of 
behavioral/emotional 
control and 
physiological well 
being. 
Results in 2 summary 
components of health 
physical and mental 
well being of the 
patient.  Aims to 
identify the positive 
and negative aspects 
of health which are 
most important to 
patients. 
   
 
 
Score on 
Scale from 
0 to 100, 
which 
represent 
the highest 
level of 
functioning.  
Poor 
HRQoL 
scores < 
35, > than 
60 best 
HRQoL.  
Good 
α>0.7 in all 
aspects 
except 
emotional 
role α>0.628 
51 52 
 
Good 
Constru
ct 
validity 
measuri
ng >0.751 
Ware & 
Sherbourn
e, 1992. 
 
Anxiety 
and 
Depressio
n 
Hospital Anxiety 
and Depression 
Scale (HADS) 
Measure anxiety and 
depression in non-
psychiatric 
populations 
Comprises 14 
Each 
question 
scores 0 to 
3.  Total 
scores 0 to 
Good 
α = 0.93 -
0.98, t = 
0.93-0.9724 
53 54 
Good 
Range 
0.6-0.824 
53 
Zigmond 
and Snaith, 
1983. 
 
 
questions.  Seven 
questions for anxiety 
(HADS-A) and seven 
questions for 
depression (HADS-D).  
42.  No 
anxiety or 
depression 
< 7, mild 8 
to 10, 
moderate 
11 to 15 
and severe 
> 16.   
 
 
Ability to 
approach 
Illness 
Multidimension
al Health Locus 
of Control Form 
C (MHLOC 
Form C) 
Measures self related 
beliefs, comprised 4 
scales namely: 
Internal, Chance, 
doctors and other 
people Internal and 
chance scales 
comprise 6 questions, 
doctors and other 
people comprise 3 
questions.  A total of 
18 questions.  
Measured 
on a 6 point 
likert scale 
ranging 
from: 1 
‘strongly 
disagree’ to 
6 ‘strongly 
agree’.  
Scores on 
the Internal 
and chance 
subscales 
range from 
6 to 36, 
with the 
doctors and 
other 
people 
subscales, 
scores 
ranging 
from 3 to 
18, higher 
scores 
suggest 
stronger 
beliefs in 
that area.  
The 
minimum 
score is 3 
and the 
maximum 
is 108. 
Good 
α = 0.60-
0.75 
Internal 
consistenc
y measures 
0.71-0.87 
t >0.8033 58 
Good 
r =0.38-
0.65 
(p<0.001
)33 58 
Wallston et 
al., 1994 
Michielsen 
et al., 2006 
Self 
Esteem 
The Rosenberg 
Self Esteem 
Scale (RSES) 
Measures 10 items 
related to  self esteem 
. Includes feelings of 
self worth and self 
acceptance with 5 
positive worded 
questions and 5 
negatively worded 
questions.  The 
negative items have 
their scores reversed 
prior to analysis.   
Each 
question 
measured 
on a 4 point 
scale. One 
total score. 
Results 
range  from 
0-30. 
Scores < 
15 
suggests 
low self 
esteem.   
Good 
α = 0.78-
0.89 
t = 0.63-0.92 
Internal 
consistenc
e 0.7756 57 
Good 
 r =0.57-
0.79 
(p<0.01)5
5 57 
Rosenberg
, 1965 
 
Table 2: Description of Questionnaires used for data collection.  
Results 
Descriptive statistics were used to report demographic details.  Individual scoring 
methods for each of the questionnaires confirmed participant’s symptom experience, if 
they satisfied the requirements of the American CDC Criteria for CFS/ME6 and the ACR 
criteria for FM.7   
Descriptive Analysis 
 
The final sample comprised CFS/ME n = 101 and FM n = 107 participants.  All 
were > 16, with the age ranging between 17-75 years, and all were eligible for 
inclusion.  Incomplete data sets were omitted.  The Mean (M) age of the CFS/ME          
(n = 101) group was M = 45.52 years and the Standard Deviation (SD) was 12.52, and 
for FM (n = 107), M = 47.20, SD = 10.77. The CFS/ME sample comprised 85.2 %         
(n = 86) females and 14.8 % (n = 15) males.  The FM group comprised 88.9 % (n = 95) 
females and 11.2 %   (n = 12) males.   
CFS/ME 45.5%, (n = 46) participants were more readily diagnosed by a General 
Practitioner.  In the case of FM a greater portion were diagnosed by a Rheumatologist 
57.9% (n = 62). 
All participants with CFS/ME confirmed that they had experienced their symptoms for the 
required > 6 months, and > 3 months for a FM diagnosis.7, 15  The CFS/ME group 
experienced their symptoms for a M = 10.69 years SD = 8.91, ranging from 1 year to 37 
years.  Participants with FM experienced symptoms for ranging from 1 year to 28 years, 
M = 12.62 years SD = 9.85. 
All participants experienced more than the minimum requirement of > 5 symptoms listed 
by the American CDC criteria, 7.9% CFS/ME (n = 8) and FM 1.8% (n = 2) groups.  With 
both groups experiencing > 4 symptoms required confirming the requirements of the 
CFS/ME criteria.6 17  The maximum number of 8 additional symptoms was experienced 
by the CFS/ME 49.0%  (n = 51) and FM 59.8% (n = 61) groups. 
The CFS/ME group (n = 101) had a Median score of 8 and Mode of 6 pain points, below 
the minimum requirement of 11.  The FM (n = 107) group presented with a Median of 14 
and Mode of 18 pain points, based on the ACR diagnostic criteria for FM,7 exceeding the 
minimum required number of 11 pain points.  The most frequent number of pain points 
reported by the CFS/ME group were 6 (n = 14), followed by 10 and then 8 pain points   
(n = 12).  In the FM group the most frequently reported number of pain points were 18   
(n = 31 participants) followed by 16 and 14 (n = 14 participants). The total number of 
participants with > 11 pain points for CFS/ME was 29.7% (n = 30) and FM was 76.6%   
(n = 82). Figures 1 and 2 illustrate the areas of the body based on the MPQ which 
incorporate the ACR criteria for FM pain points, where participants indicated they 
experienced their pain.   
(Insert Figure 1)  
 
The total numbers of pain points were calculated by assessing the areas where 
participants indicated their pain was located. The main areas identified by both groups 
were the cervical areas 52.5% (n = 53), CFS/ME and for FM 64.5% (n = 69) and the 
upper shoulders 52.5% (n = 53), for CFS/ME and 72% (n = 77), for FM (Fig.1).  In 
addition, 66.4% (n = 71) of FM participants experienced pain in their lower backs.  This 
was also the second most problematic area of pain recorded for the CFS/ME group 
31.7% (n = 32) to 45.5% (n = 46) all these areas included the ACR pain points (Fig.1).  A 
higher portion of the FM group reported pain in these areas when compared to the 
CFS/ME group. 
(Insert Figure 2)  
 
The main areas of pain identified for the anterior view of the body (Fig. 2) were the neck 
for 36.6% (n = 37) for the CFS/ME group, and 54.2% (n = 58) of the FM group, but in 
this instance no pain points were included.  The chest area, which includes the pain 
points, were found to be problematic for both groups with 43.0% (n = 46) of the FM 
participants and 23.3% of the CFS/ME participants selecting this area.  In addition 
participants were able to indicate areas of the body they experienced pain which did not 
incorporate the ACR pain points, concluding that pain was experienced in multiple areas 
of the body including the face and head which are not indicative of the ACR pain points 
for diagnosis. 
Table 3 presents the results for the participants Mean scores for the individual 
questionnaires for both groups.  
Table 3: Description of the Valid and reliable questionnaires to measure the symptoms 
in the CFS/ME and FM group 
Variable Mean 
score 
CFS/ME 
Mean 
score 
FM 
Cut off Scores 
American CDC symptoms Inventory    
Sore throat 3.79 3.59  
Tender Lymph Nodes and or Swollen 
Glands 
4.60 4.25  
Fatigue After Exertion 12.43 12.99  
Muscle Aches and Pains 9.51 13.79  
Joint Pain 7.78 11.48  
Unrefreshing Sleep 10.97 13.19  
Headaches 6.27 6.96  
Memory and or Concentration 
Problems 
9.37 9.62  
Total Degree of Distress 
 
64.72 75.87 N/A 
FIQ    
Total Physical Impairment   57.55 64.89  
No of days felt well 8.28 8.49  
No of days missed work 5.48 5.80  
Impact of symptoms on work 7.04 7.50  
How bad pain has been* Mdn 7.0 8.0  
How tired have you been* Mdn 9.0 9.0  
Feeling in the morning 6.65 7.97  
Morning stiffness*  Mdn 7.0 8.0  
How tense/ nervous  4.50 5.64  
How depressed or blue 4.21 5.48  
Overall Score FIQ 
 
62.97 70.60 > 50 confirmed FM >70 Severe FM 
MPQ    
Number of pain points 8.49 13.59  
Total Sensory Score 15.10 19.36  
Total Affective Score 7.53 10.57  
Total Evaluative Score 2.89 3.76  
Total Score Miscellaneous 5.71 7.97  
Sum of All dimensions of MPQ 
 
31.23 41.65 Scores between 24% to 50% of total score confirm severe pain 
MFI    
Total Score General Fatigue 16.60 16.83  
Total Score Physical Fatigue 16.49 16.46  
Total Score Reduced Activity 15.09 14.91  
Total Score Reduced Motivation 12.90 13.20  
Total Score Mental Fatigue 
 
15.13 15.20  
PSQI    
Sleep Duration 1.08 1.10  
Sleep Disturbance 1.82 1.85  
Sleep Latency 1.96 1.99  
Day Dysfunction due to Sleepiness 2.05 2.11  
Sleep Efficiency 1.61 1.74  
Overall Sleep Quality 2.02 1.93  
Medication to Sleep 1.39 1.45  
Total Score PSQI 
 
11.94 12.18 > 5 poor sleep quality 
SF-36 V2    
Physical Functioning 38.81 27.10  
Social Functioning 31.44 31.78  
Role Physical Functioning 23.39 22.61  
Role Mental Functioning 64.27 51.79  
Mental Health 59.65 51.82  
Vitality 14.48 13.84  
Pain 38.29 22.42  
General Health 26.07 25.85  
Change in Health 
 
41.58 30.14 Scores of 0 best health scores close to 100 poor health 
HADS    
Total Anxiety 8.52 10.60  
Total Depression 8.30 10.10  
Total Score HADS 
 
16.82 20.70 < 7 no anxiety  or depression, 8 to 9 borderline case, >11 anxiety 
and depression 
MHLOC    
Internal Sum 17.66 19.03  
Chance 17.76 16.97  
Doctors 7.46 8.10  
Other People 
 
8.29 8.0 High scores in particular area confirm beliefs in that area 
RSES    
Total RSES 14.35 15.02 < 15 poor self esteem 
FIQ 
Results for the FIQ confirm that 61.3% (n = 61) of the CFS/ME group scored > 50, 
indicative of FM symptoms present, and 13.8% (n = 14) of participants scoring > 70, 
indicative of severe symptoms of FM.28  In the FM group 80.3% (n = 86) of participants 
scored > 50 and 28.0% (n = 30) of participants scored > 70.  The FIQ total scores for the 
CFS/ME group ranged between 8.86, and 90.4, and for the FM group were between 
12.00 and 96.76.   
 
MPQ 
Results for the MPQ which poses a range of questions relating to different aspects of 
pain, including; Sensory, Affective, Evaluative and Miscellaneous, confirmed that a 
significant amount of pain was experienced by both groups.  Although there are no cut 
off scores for the MPQ, people with painful conditions will normally have scores ranging 
from 24% to 50% of the total score with an average of 30%.29, 30 
 
MFI 
Fatigue was confirmed by both groups on the 5 individual domains of the MFI (General 
fatigue, Physical Fatigue, Reduced Activity, Reduced Motivation and Mental fatigue).23  
Scores ranged between 4 and 20, with total scores not recommended.  The minimum 
score identified for the CFS/ME group was 4 for physical fatigue and reduced motivation, 
and the maximum score was 20, for the remaining items of the MFI, the minimum scores 
were identified as > 5 with the maximum score of 20.  In the CFS/ME sample, 99.0% of 
(n = 100) participants experienced fatigue on each domain of the MFI.  In the FM group 
the minimum score for general fatigue and physical fatigue was 4 with the minimum 
score on the remaining domains > 5, and the maximum score on all the domains were 
20.  In the FM sample 98.1% of (n = 105) participants experienced fatigue on all the 
domains of the MFI.  These results confirmed that both the CFS/ME and FM groups 
experienced a high level of fatigue, a symptom which is indicative of a diagnosis of 
CFS/ME and associated with FM. 
 
PSQI 
The PSQI29 confirmed poor sleep quality in 43.6% (n = 44) of CFS/ME and 47.7%         
(n = 51) of FM participants.  The number of participants who had taken Medication > 3 
times per month to assist with sleep were 39.6% (n = 40) of the CFS/ME group, and 
41.1% (n = 44) of the FM group.  The minimum total score recorded for poor sleep 
quality on the PSQI for the CFS/ME group was 5, and the maximum was 20.  The 
minimum total score on the PSQI for the FM group was 3 and the maximum score was 
21.  These findings confirm that both the CFS/ME and FM groups experienced poor 
sleep quality. 
 
SF-36 V2 
The SF-36 V225 confirmed reduced HRQoL in both groups.  Scores closer to 0 suggest 
impaired, and scores closer to 100 suggest the best HRQoL.31  The results presented in 
Table 3 confirm participants with CFS/ME and FM have a reduced HRQoL with the 
Mean scores on most of the components below 50.  The exceptions were for the mental 
health and role mental functioning components, where scores were > 50 which suggests 
participants HRQoL was not affected by their mental health.  Role physical function was 
found to have the greatest impact on both the CFS/ME and FM groups.  Role mental 
function did not have as big an impact on participants HRQoL. 
 
HADS 
The results for the total score for anxiety on the HADS24 ranged from 0 to 20 and 
confirmed that out of the total sample of CFS/ME (n = 101) 49.5% (n = 50), and FM      
(n = 107) 27.1%   (n = 29) participants, did not display symptoms of anxiety.32 There was 
a borderline case of anxiety for 14.9% (n = 15) of CFS/ME and 20.5% (n = 22) of FM 
participants, with the remaining 35.6%   (n = 36) of CFS/ME and 52.3% (n = 56) of FM 
participants confirmed as displaying symptoms of anxiety.   
The total score for depression identified that 37.6% (n = 38) of CFS/ME and 28.0%       
(n = 30) of FM participants did not display symptoms of depression.  There was a 
borderline case for depression for 32.6% (n = 33) of CFS/ME and 30.8% (n = 33) of FM 
participants.  The remaining 29.7% (n = 30) of CFS/ME and 41.1% (n = 44) of FM 
participants in this sample expressed symptoms of depression.   
The total score on the HADS confirmed that 9.9% (n = 10) of CFS/ME and 2.8% (n = 3) 
of FM participants did not display symptoms of anxiety and depression.  There was a 
possible caseness for 15.8% (n = 16) of the CFS/ME and 4.8% (n = 5) of FM participants 
for anxiety and depression.  The remaining 74.0 (n = 75) of CFS/ME and 92.5% (n = 99) 
of FM participants confirmed they were affected by symptoms of anxiety and depression.  
These results confirmed that both groups experience some degree of anxiety and 
depression, with the FM group displaying higher scores on the HADS than the CFS/ME 
group. 
 
 
 
 
 
 
 
 
 
MHLOC 
A total score is not recommended for the MHLOC,26 the scores for the internal and 
chance scales range between 6 and 36.33  The scores for the doctors and powerful other 
scales range between 3 and 18.  Higher scores on a particular scale suggest stronger 
beliefs in that area, either internal or external locus of control.  The Mean score for the 
internal and chance scores for CFS/ ME are just on the Median (n = 18), for these 
subscales and below the Median score (n = 9) for the external scores (doctors and other 
people).  Results for the FM group identify slightly higher scores than the Median score 
for the internal sum and below the Median scores for chance, doctors and other people.  
The minimum score for both groups on the internal and chance scales were 6 where the 
maximum score was 33, for the CFS/ME group and 35 for the FM group on the internal 
scale.  The maximum result on the chance scale for the CFS/ME group were 33 and for 
the FM group 32.  The minimum score calculated for the doctors and other people 
scales were 3 for both groups.  The maximum score recorded for the CFS/ME group on 
the doctors domain was 17, and for the FM group was recorded as 18.  The maximum 
score recorded for other people for both groups was 18.  The results presented suggest 
on average the CFS/ME and FM groups present with similar scores. 
RSES 
The RSES34 scores range from 0 to 30.  Results did not confirm that either the CFS/ME 
or FM groups presented with scores > 25.  In the CFS/ME group 36.6% (n = 37) and in 
the FM group 53.3% (n = 57) of participants confirmed scores < 15.  These results 
suggest that the FM group experienced a lower degree of self esteem than the CFS/ME 
group. 
Discussion 
Unlike historical research into CFS/ME and FM this research measured the symptoms of 
CFS/ME and FM using self assessment questionnaires to confirm and reaffirm the 
nature of symptoms associated with CFS/ME and FM.  The characteristics, such as age 
and gender of the CFS/ME and FM groups are supported by historical findings of 
CFS/ME and FM. 5 35  Both groups confirmed their diagnosis by satisfying the 
requirements of the CFS/ME criteria6 and the FM criteria.7   
The specialty of Clinicians who diagnosed the participants in this sample of 
CFS/ME and FM is also characteristic of earlier findings. Diagnosis of CFS/ME by a GP 
are not unexpected where in contrast people with FM are more readily assessed and 
receive their diagnosis from a Rheumatologist or a General Practitioner.36 In contrast 
people with CFS/ME are not readily assessed or referred onto specialist services, as 
supported by the current findings.3  This suggests that people with FM more readily have 
access to specialist services than patients with CFS/ME. 
 
The results from the CFS/ME group confirmed that not all participants satisfied the 
minimum of 11 pain points to comply with the requirements of the FM criteria.  However, 
the MPQ presents clear evidence that the CFS/ME group experienced pain in different 
areas of the body, confirming pain is as debilitating a symptom as in FM.  This is 
revealing as the reviewed FM criteria 2 has removed the highly prescriptive pain points, 
and focuses on areas of pain, to assess the patient holistically.  Furthermore there is 
evidence which highlights that the complex nature of this pain assessment has led to it 
being performed incorrectly or omitted by Clinicians as a diagnostic tool for FM.37 Taking 
all these factors into consideration it may be reasonable to concluded in this instance 
that this sample of participants satisfied the requirements of the FM criteria.8 In contrast 
the FM group confirmed they met the requirements of the CFS/ME criteria. 
Pain is widely documented as a defining feature for a diagnosis of FM2,7 and fatigue has 
been the primary symptom associated with a diagnosis of CFS/ME.18,38  Taking this into 
consideration with the results presented from the MPQ, PSQI and MFI confirmed that 
both groups experienced pain and fatigue which impacted on their HRQoL.  The high 
levels of pain identified reflect the findings from studies comparing CFS/ME and FM with 
other painful conditions such as chronic pain and arthritis, which identified their pain was 
equivocal.39,40  The findings presented from the MFI confirms that the debilitating 
fatigue that plagues people in CFS/ME is also an issue for people with FM.  This 
suggests that the symptom of fatigue in FM is as much a management priority as pain, 
as it is a distressing symptom identified as negatively impacting on a patient’s quality of 
life 23 In view of these findings and current research, this suggests that the individual 
diagnostic criteria for CFS/ME and FM are sensitive towards the diagnosis they are 
designed for.  Therefore consideration should be given to reviewing current published 
guidelines for CFS/ME in view of the arguments provided for not creating guidelines for 
FM.17   
In addition to pain and fatigue our findings confirmed that both groups experienced poor 
sleep quality, and reduced HRQoL with the list of symptoms being extensive.  
Furthermore participants in both groups experienced these symptoms to a debilitating 
degree, which caused impairment and had an impact on their daily lives.  These groups 
did not confirm high levels of anxiety, depression or low self esteem, which are in 
contrast to historical reports, suggesting this is not the main pressing issues in CFS/ME 
and FM.34, 35, 3, 41 With the current lack of successful management plans and taking these 
findings into consideration, improvement to HRQoL should be given priority in patients 
with CFS/ME and FM.  This is pertinent as it has been identified that CFS/ME and FM 
negatively impact on occupational, social, personal and economical aspects, which are 
frustrating and devastating for a person who previously enjoyed good health.42, 43 These 
results raise questions regarding compartmentalizing the symptoms into either a 
diagnosis of CFS/ME or FM.  Fatigue, the main symptom used to make a diagnosis 
of CFS/ME and Pain, the primary diagnostic symptom of FM, have both been 
confirmed as problematic for both groups.  These findings suggest that there is a 
grey area between the two diagnoses.  The data presented suggests that the 
similarities between the symptoms measured outweigh any differences.  The 
evidence presented provides compelling debate to recommend that further 
research in this area is undertaken.  This would further investigate the 
significance of the current findings, to identify if there maybe ramifications for the 
classification of CFS/ME and FM and its future management. 
Strengths and Limitations of this study 
To our knowledge this is the first study to assess the symptom experience of CFS/ME 
and FM using the methods described.  This study brings attention to an area with 
CFS/ME and FM which has not been researched in a number of years.   
 
 
 
Conclusion 
This preliminary data provided evidence of a high level of symptoms which impact on 
daily life.  Furthermore the results suggest that both groups experience a high level of 
pain which is not always localised to the prescriptive pain areas outlined by the ACR 
criteria for FM.  In addition both groups experience debilitating fatigue.  The strong 
evidence presented in this first part of the study, alludes to the fact that both CFS/ME 
and FM may have a similar symptoms experience, and this should be afforded more 
investigation.  
 
What is already known on this topic 
 
Both groups share similar symptoms but it has not been confirmed whether they are the 
same syndrome.  Historically pain is the main diagnostic factor in FM and fatigue is the 
main diagnostic factor in CFS/ME.  Separate diagnostic criteria exist for CFS/ME and 
FM but their trajectory of management options may be different based on diagnosis.  
Research into this area is obsolescent. 
 
What this research adds 
 
To date this approach to assessing the symptom experience of CFS/ME and FM has not 
been used.  This study confirms that fatigue associated with CFS/ME and pain 
associated with FM maybe problematic for each group regardless of diagnosis.  Pain 
and Fatigue were historically key defining symptoms. This study highlights that in the 
absence of specific aetiology confirming the cause of CFS/ME and FM there is a need to 
address HRQoL where management options are limited or unsuccessful.  This research 
provides a basis for future research to establish if the syndrome experience of CFS/ME 
and FM are the same.  
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